期刊文献+
共找到654篇文章
< 1 2 33 >
每页显示 20 50 100
Inhibitory Effects of Natural Compound Alantolactone on Human Non-small Cell Lung Cancer A549 Cells
1
作者 ZONG Min-ru ZHAO Ying-hao +3 位作者 ZHANG Kun YANG Long-fei ZHENG Yong-chen HE Cheng-yan 《Chemical Research in Chinese Universities》 SCIE CAS CSCD 2011年第2期241-244,共4页
Alantolactone is a natural compound identified from the roots of Inula helenium L. that has multiple bio-activities. We examined its inhibitory effects on human non-small cell lung cancer(NSCLC) A549 cells. The an-t... Alantolactone is a natural compound identified from the roots of Inula helenium L. that has multiple bio-activities. We examined its inhibitory effects on human non-small cell lung cancer(NSCLC) A549 cells. The an-tiproliferative effect of alantolactone on A549 cells was investigated via MTT[3′-(4,5dimethylthiazol-2-yl)-2,5- diphenyl tetrazolium bromide] assay and its apoptosis-inducing effect was determined by Hoechst staining and flow cytometry. We found that alantolactone significantly inhibited the proliferation of A549 cells and induced morphological changes typical for apoptosis. Flow cytometry analysis indicates dose-dependent cell cycle retardation at G0/G1 and S stages. The results indicate that alantolactone could be an attractive small-molecular natural compound for further development as a therapeutic drug against NSCLC. 展开更多
关键词 ALANTOLACTONE Non-small cell lung cancer(NSCLC) a549 PROLIFERATION APOPTOSIS
下载PDF
The Role of CHMP4C on Proliferation in the Human Lung Cancer A549 Cells
2
作者 Kang Li Jianxiang Liu +6 位作者 Mei Tian Chunnan Piao Jianlei Ruan Ling Gao Xuesong Qi Gang Gao Xu Su 《Journal of Cancer Therapy》 2015年第15期1223-1228,共6页
The human lung cancer has high incidence rate and mortality among the carcinoma. The research on enhancing the efficacy of therapy for lung cancer is significant. A resent research found that as a subunit of ESCRT-III... The human lung cancer has high incidence rate and mortality among the carcinoma. The research on enhancing the efficacy of therapy for lung cancer is significant. A resent research found that as a subunit of ESCRT-III, CHMP4C functioned to retard abscission timing to coordinate midbody resolution and prevent accumulation of DNA damage in the abscission checkpoint through phosphorylated by AuroraB. In the current study, we evaluated the possible mechanism of the effects of CHMP4C inhibition on cell cycle and cell survival in A549 cells. We found that CHMP4C knockdown caused lagging S phase in cell cycle through enhancing the phosphorylation of Rb, raising the expression of cyclin B1-cdc2 and suppressing the activation of cyclin A. Meanwhile, CHMP4Cdeletion depressed cell survival via decreasing cell viability and increasing caspase 3/7 activity. This study may promote new significant reference and advance for the mechanism underlying specific function of CHMP4C as well as further research on enhancing therapy effect on non-small lung cancer. 展开更多
关键词 The human lung cancer a549 CHMP4C SIRNA
下载PDF
Highly Efficient Labeling of Human Lung Cancer Cells Using Cationic Poly-L-lysine-Assisted Magnetic Iron Oxide Nanoparticles 被引量:4
3
作者 Xueqin Wang Huiru Zhang +1 位作者 Hongjuan Jing Liuqing Cui 《Nano-Micro Letters》 SCIE EI CAS 2015年第4期374-384,共11页
Cell labeling with magnetic iron oxide nanoparticles(IONPs)is increasingly a routine approach in the cellbased cancer treatment.However,cell labeling with magnetic IONPs and their leading effects on the biological pro... Cell labeling with magnetic iron oxide nanoparticles(IONPs)is increasingly a routine approach in the cellbased cancer treatment.However,cell labeling with magnetic IONPs and their leading effects on the biological properties of human lung carcinoma cells remain scarcely reported.Therefore,in the present study the magnetic c-Fe2O3nanoparticles(MNPs)were firstly synthesized and surface-modified with cationic poly-L-lysine(PLL)to construct the PLL-MNPs,which were then used to magnetically label human A549 lung cancer cells.Cell viability and proliferation were evaluated with propidium iodide/fluorescein diacetate double staining and standard 3-(4,5-dimethylthiazol-2-diphenyl-tetrazolium)bromide assay,and the cytoskeleton was immunocytochemically stained.The cell cycle of the PLL-MNPlabeled A549 lung cancer cells was analyzed using flow cytometry.Apoptotic cells were fluorescently analyzed with nuclear-specific staining after the PLL-MNP labeling.The results showed that the constructed PLL-MNPs efficiently magnetically labeled A549 lung cancer cells and that,at low concentrations,labeling did not affect cellular viability,proliferation capability,cell cycle,and apoptosis.Furthermore,the cytoskeleton in the treated cells was detected intact in comparison with the untreated counterparts.However,the results also showed that at high concentration(400 lg m L-1),the PLL-MNPs would slightly impair cell viability,proliferation,cell cycle,and apoptosis and disrupt the cytoskeleton in the treated A549 lung cancer cells.Therefore,the present results indicated that the PLL-MNPs at adequate concentrations can be efficiently used for labeling A549 lung cancer cells and could be considered as a feasible approach for magnetic targeted anti-cancer drug/gene delivery,targeted diagnosis,and therapy in lung cancer treatment. 展开更多
关键词 Magnetic labeling Iron oxide nanoparticles POLY-L-LYSINE human a549 lung cancer cells cancer treatment
下载PDF
Continuous intravenous infusion of recombinant human endostatin using infusion pump plus chemotherapy in non-small cell lung cancer 被引量:3
4
作者 Zhi-Quan Qin Si-Fu Yang +7 位作者 Yun Chen Chao-Jin Hong Tong-Wei Zhao Guo-Rong Yuan Liu Yang Liang Gao Xiao Wang Li-Qin Lu 《World Journal of Clinical Cases》 SCIE 2022年第4期1164-1171,共8页
BACKGROUND Lung cancer is one of the deadliest cancers in the world with the highest incidence and mortality rate among all cancers.Non-small cell lung cancer(NSCLC)accounts for approximately 80%of primary lung cancer... BACKGROUND Lung cancer is one of the deadliest cancers in the world with the highest incidence and mortality rate among all cancers.Non-small cell lung cancer(NSCLC)accounts for approximately 80%of primary lung cancer.However,efficacy and safety of the current regimens for NSCLC is unsatisfactory.Therefore,there has been an increasing urgency for development of potential therapeutic therapies for NSCLC.AIM To investigate the therapeutic outcomes and safety of continuous intravenous infusion of recombinant human endostatin(Rh-endostain)using an infusion pump in retreated advanced NSCLC.METHODS Patients with retreated advanced NSCLC who were admitted to Zhejiang Provincial People's Hospital from October 2017 to April 2019 were recruited.These patients received continuous intravenous infusion of Rh-endostain using an infusion pump.Objective response rate(ORR),clinical benefit rate(CBR),median progression-free survival(mPFS),and incidences of adverse events(AEs)were analyzed after treatment.RESULTS A total of 45 patients with retreated advanced NSCLC were included,and all of them were evaluated.In these patients,ORR was 22.2%,CBR was 84.4%,and mPFS was 5.3 mo.The following AEs were observed,decreased hemoglobin(34 cases,75.6%),nausea/vomiting(32 cases,71.1%),elevated transaminase(24 cases,53.3%),leukopenia(16 cases,35.6%),thrombocytopenia(14 cases,31.1%),and constipation(1 case,3.4%).None of the patients had leukopenia,nausea/vomiting,and constipation of grade III and above.CONCLUSION The patients showed improved adherence to 5-d continuous intravenous infusion of Rh-endostain using an infusion pump.Favorable efficacy and safety of this treatment regimen were achieved in retreated advanced NSCLC. 展开更多
关键词 Non-small cell lung cancer CHEMOTHERAPY Recombinant human endostatin Continuous intravenous infusion
下载PDF
Efficiency of combining pomegranate juice with low-doses of cisplatin and taxotere on A549 human lung adenocarcinoma cells 被引量:1
5
作者 Nasser Mohamad Hijazi Akram +5 位作者 Sayed Ahmad Bouchra Jamal Eddine Zeinab Ibrahim Sajida Rammal Hassan Al Rekaby Abd-El-Ameer Nasser Mouhamad 《Asian Pacific Journal of Tropical Biomedicine》 SCIE CAS 2018年第1期19-24,共6页
Objective: To test the coalescence effect of two chemotherapy drugs at low effective dose(cisplatin and taxotere) combined with pomegranate juice on A549 cancer cells. Methods: Infrared spectroscopy method is a qualit... Objective: To test the coalescence effect of two chemotherapy drugs at low effective dose(cisplatin and taxotere) combined with pomegranate juice on A549 cancer cells. Methods: Infrared spectroscopy method is a qualitative test that was performed to ensure the existence of the phytochemicals providing the antioxidant activity through the presence of the hydroxyl group(-OH). The viability of A549 cell line and normal MCs was tested using the neutral red uptake, Clonogenic survival, XTT and Cell migration assays. Results: Our results showed that this combination firstly led to a greater decrease in the viability of cells comparing to those treated with chemotherapy drugs alone, and secondly led to a significant reduction in cell migration. Conclusions: These data suggest a synergistic effect between the pomegranate and cisplatin which makes probably this combination a powerful option for treating lung adenocarcinoma and in parallel minimizing the systemic side effects. 展开更多
关键词 lung cancer Chemotherapy CISPLATIN TAXOTERE POMEGRANATE a549 cells
下载PDF
Alterations and Its Mechanisms of Wnt Signal Pathway in Human High-matastatatic Large Cell Lung Cancer Cell Line L9981 by Transfecting with Nm23-H1 Gene 被引量:1
6
作者 Junke FU Zhe WANG +7 位作者 Sen WEI Gang CHEN Zhigang LI Jun CHEN Hongyu LIU Zhihao WU Ke XU Qinghua ZHOU 《中国肺癌杂志》 CAS 2009年第6期477-479,共3页
Backgroud and Objective Tumor metastasis is not only the malignant marker and characteristics of lung cancer, but also the main cause of failure to cure and lose their life of the
关键词 肺癌 扩散 临床 化疗
下载PDF
ANTI-HUMAN LUNG GIANT CELL CANCER (PG) EFFECT OF HUMAN LAK CELLS IN VITRO AND IN NUDE MICE
7
作者 邓鸿业 丁桂凤 +3 位作者 邓玉兰 方伟岗 吴秉铨 孙靖 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 1991年第2期30-32,共3页
Human LAK cells were prepared by culturing normal human peripheral blood mononuclear cells (PBMC) with or without rIL-2 and assayed for T cell surface markers as well as anti-tumor activity against PC in vitro and in ... Human LAK cells were prepared by culturing normal human peripheral blood mononuclear cells (PBMC) with or without rIL-2 and assayed for T cell surface markers as well as anti-tumor activity against PC in vitro and in nude mice. Although the percentages of T3, T4, and T8 positive cells in rIL-2-activated cells did not differ significantly from those of control cells in vitro, the former showed stronger cytotoxicity than control cells to PG tumor cells in vitro. In vivo, LAK cells completely inhibited the growth of PG tumor in nude mice, whereas PBMC control cells were to be of no effect. The anti-tumor effect of human LAK cells in nude mice may offer a useful model to study the role of human LAK cells against human tumor in vivo. 展开更多
关键词 LAK EFFECT OF human LAK cellS IN VITRO AND IN NUDE MICE ANTI-human lung GIANT cell cancer PG
下载PDF
Reversal effect of recombinant human Endostatin on cisplatin resistance in A549/DDP human lung adenocarcinoma cells in vitro
8
作者 Yuxuan Che Jiawei Xu +3 位作者 Shuang Su Xiuhua Sun Man Li Yang Zhang 《The Chinese-German Journal of Clinical Oncology》 CAS 2013年第11期509-515,共7页
Objective: Recombinant human Endostatin (rh-Endostatin, YH-16) can reverse cisplatin resistance in A549/DDP cells. However, the possible effect of rh-Endostatin in reversing DDP-resistance in A549/DDP cells and the... Objective: Recombinant human Endostatin (rh-Endostatin, YH-16) can reverse cisplatin resistance in A549/DDP cells. However, the possible effect of rh-Endostatin in reversing DDP-resistance in A549/DDP cells and the mechanism are needed to be investigated. Methods: Lung adenocarcinoma cell line A549 and its DDP-resistant cell line A549/DDP were treated with DDP and/or recombinant human Endostatin. Difference in drug resistance was analyzed between different regi- mens and between different cell lines after a 72 h-treatment in vitro. And below the non-cytotoxic concentration of rh-End- ostatin, the possibility of rh-Endostatin in reversing DDP-resistance in A549/DDP was evaluated. The resistance protein which was detected in the study included P glycoprotein (P-gp) and topoisomerase II (Topo-II). Results: Rh-Endostatin below 400 IJg/mL showed no cytotoxicity in either A549 or A549/DDP after 72 h-treatment with it. The inhibited concentration of 50% (IC50) observed for DDP was (0.79 _+ 0.05) IJg/mL in A549 and (13.2 + 1.1) in A549/DDP respectively. IC50 was reduced to 2.57 + 0.05 #g/mL in A549/DDP treated by rh-Endostatin below the non-cytotoxic concentrations in combination with DDP, with a reversal fold (RF) of 5.14 and a relative reversal rate of 85.6%. Apoptotic rates were 2.01%, 13.47% and 29.26% re- spectively for cells treated with rh-Endostain, DDP, and the combination. The rate of the A549/DDP control group was 0.99%. The expression level of P-gp or Topo-II was higher in A549/DDP cells than in A549 cells. Rh-Endostatin may partially reverse DDP-resistance in A549/DDP cells in vitro, with a probable mechanism related to lowering expression of P-gp and Topo-II. Conclusien: Rh-Endostatin of non-cytotoxic dose partially reversed cisptatin resistance in cisplatin-resistant human lung adenocarcinoma cell line A549/DDP. Rh-Endostatin reversed the resistance of A549/DDP cells to DDP, which may be related to decreased protein expression of P-gp and Topo-II in A549/DDP cells. 展开更多
关键词 recombinant human ENDOSTATIN lung neoplasms a549/DDP cell line drug resistance
下载PDF
Effects of paclitaxel on cell proliferation and apoptosis and its mechanism in human lung adenocarcinoma A549 cells
9
作者 Baoan Gao Chunling Du +2 位作者 Wenbo Ding Shixiong Chen Jun Yang 《Journal of Nanjing Medical University》 2006年第6期360-364,共5页
Objective: To investigate the effect of paclitaxel on cell proliferation and apoptosis of human lung adenocarcinoma A549 cells line and its mechanism in vitro. Methods : Cell growth inhibition of paclitaxel on A549 ... Objective: To investigate the effect of paclitaxel on cell proliferation and apoptosis of human lung adenocarcinoma A549 cells line and its mechanism in vitro. Methods : Cell growth inhibition of paclitaxel on A549 cells was analyzed by MTT assay. Cell apoptosis was detected by DNA cytofluorometry, Hoechst33258 staining when treated with paclitaxel for 48 hours. Meanwhile, Cell cycle and apoptotic rate were analyzed by flow cytometry. The protein expressions of Bax and Bcl-2 were studied by Western Blot. Results: Paclitaxel inhibited the proliferation of A549 cells in a time-and dose-dependant manner. Hoechst33258 staining indicated that apoptosis was induced by paclitaxel. After treated for 48 hours, cell apoptosis rates of 25 nmo1/L, 50 nmol/L and 100 nmol/L paclitaxel groups were 11.52 ± 1.94% ,17.73 ±2.53%, and 29.32 ±5.51% respectively, which were significantly higher than those of control group 5.88 ±1.07%(all P 〈 0.01 ), and apoptosis rate increased in dose-dependant manner. Meanwhile, G2/M stage cell percentage of 25 nmol/L, 50 nmol/L and 100 nmol/L paclitaxel groups were 42.52 ± 6.25%, 40.46 ± 5.81%, and 35.34 ±6.17% respectively,which were significantly higher than that of control group 22.32 ± 3.30%(all P 〈 0.01 ); Western blot showed that paclitaxel increased the expression of Bax and decreased the expression of Bcl-2 in dose-dependant manner. Conclusion: Paclitaxel can inhibit A549 cell proliferation in a time-and dose-dependant manner. Its mechanism may be related to arresting cell cycle in G2/M stage and induce cell apoptosis by up-modulating Bax expression and down-modulating Bcl-2 expression. 展开更多
关键词 PACLITAXEL cell cycle APOPTOSIS human lung adenocarcinoma a549 cells
下载PDF
Effects of recombinant human endostatin on therapeutic effect, angiogenesis, tumor cell proliferation and migration in patients with non-small cell lung cancer
10
作者 Min-Wen Ling Jie Wang Hong-Zi Ding 《Journal of Hainan Medical University》 2019年第2期57-61,共5页
Objective:To investigate the effects of recombinant human endostatin on therapeutic effect, angiogenesis, tumor cell proliferation and migration in patients with non-small cell lung cancer.Methods: A total of 100 pati... Objective:To investigate the effects of recombinant human endostatin on therapeutic effect, angiogenesis, tumor cell proliferation and migration in patients with non-small cell lung cancer.Methods: A total of 100 patients with non-small cell lung cancer treated in our hospital from September 2015 to March 2018 were selected as research subjects.They were randomly divided into observation group and control group, 50 cases in each group.The control group was treated with gemcitabine plus cisplatin, while the observation group was combined with Endostar treatment on the basis of the control group. Observed and compared the expression of the therapeutic effect[including cytokeratin 19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA) and carbohydrate antigen (CA50)], angiogenesis[including vascular endothelial growth factor (VEGF) and hypoxia inducible factor (HIF-1 alpha)], tumor cell proliferation[including insulin-like growth factor (IGF-1) and insulin-like growth factor receptor -7 (IGFBP-7)] and migration[including high mobility group protein AT-hook2 (HMGA2) and high mobility group protein B1 (HMGB1)]in two groups.Results: The two groups showed significant changes in the therapeutic effect, angiogenesis, proliferation and migration of tumor cells. Before treatment, there was no significant difference in all levels between the two groups. After treatment, the levels of CYFRA21-1, CEA, CA50, VEGF, HIF-1a, IGF-1, HMGA2 and HMGB1 in the two groups were significantly lower than those before treatment, while the levels of IGFBP-7 were significantly higher than those before treatment. After treatment, the levels of CYFRA21-1, CEA, CA50, VEGF, HIF-1a, IGF-1, HMGA2 and HMGB1 in the observation group were significantly lower than those in the control group, while the levels of IGFBP-7 were significantly higher than those in the control group. Conclusions: Recombinant human endostatin can enhance the therapeutic effect of non-small cell lung cancer patients, reduce angiogenesis, inhibit tumor cell proliferation and migration. 展开更多
关键词 Non small cell lung cancer RECOMBINANT human VASCULAR ENDOTHELIN Treatment effect ANGIOGENESIS TUMOR cells
下载PDF
The Difference of the Copy Number Variation and Loss of Heterozygosity of Human Lung Large Cell Cancer Cell Line with Different Metastatic Potential
11
作者 Bin HU Xiaoming QIU Ting WANG Yu FAN Li MA Jun CHEN Sen WEI Zhigang LI Hongyu LIU Haisu WAN Zhihao WU Qinghua ZHOU 《中国肺癌杂志》 CAS 2009年第6期512-514,共3页
Background and Objective It has been proven that copy number gain/or loss (copy number variation CNV) in uences gene expression and result in phenotypic variation by
关键词 肺癌 癌细胞 CNV 治疗 疗效
下载PDF
The Difference of Gene Expression Prof ile in Human Large Cell Lung Cancer Cell Lines with Different Metastatic Potential
12
作者 Xiaoming QIU Ting WANG Yu FAN Li MA Jun CHEN Sen WEI Zhigang LI Hongyu LIU Haisu WAN Zhihao WU Qinghua ZHOU 《中国肺癌杂志》 CAS 2009年第6期496-497,共2页
Background and Objective Lung cancer is the most lethal malignangy that threatens human heath and lives nowadays in the world, and meanwhile is also the one with worst
关键词 肺癌 扩散 医学 治疗
下载PDF
The Effects of Intracellular Glutathione Content on the Sensitivity of Methylseleninic Acid to Human High-metastatic Large Cell Lung Cancer Cell Line L9981
13
作者 Chengfei LIU Jun CHEN +5 位作者 Liya SUN Yu ZHU Ting WANG Na-galakshmi NADIMINTY Allen C. GAO Qinghua ZHOU 《中国肺癌杂志》 CAS 2009年第6期510-511,共2页
Background and Objective Lung cancer has the fastest increasing rate of morbidity and mortality all over the world and appears to be one of the most dangerous malignant tumors
关键词 肺癌 癌细胞 治疗 疗效
下载PDF
Effects of Methylseleninic Acid on the Proliferation and Cell Cycle in Human High Metastatic Large Cell Lung Cancer Cell Line L9981 and Its Molecular Mechanism
14
作者 Xiaorong ZHONG Yu FAN Li MA Jun CHEN Sen WEI Zhigang LI Hongyu LIU Haisu WAN Zhihao WU Qinghua ZHOU 《中国肺癌杂志》 CAS 2009年第6期498-499,共2页
Background and Objective Lung cancer is the rst killer of human being in the whole world. Recently, although many treatment strategies have been developed, the anti-cancer effects
关键词 肺癌 临床 治疗 疗效
下载PDF
Down-regulation and It's Molecular Biology of Nm-23H1 gene Transfection on Ras-to-MAPK Signal Transduction Pathway in Human High-metastatic Large Cell Lung Cancer Cell Line L9981
15
作者 Yin LI Jianjun QIN +9 位作者 Yun WANG Jun CHEN Sen WEI Gang CHEN Zhigang LI Hongyu LIU Haisu WAN Zhihao WU Ke XU QInghua ZHOU 《中国肺癌杂志》 CAS 2009年第6期487-489,共3页
Backgroud and Objective Tumor metastasis is not only the malignant marker and characteristics of lung cancer, but also the key cause of failure to cure and lose their life of the patients
关键词 肺癌 化疗 疗效 MAPK
下载PDF
Influence of Nm23-H1 Gene Site Mutagenesis on Invasive And Metastatic Phenotype in Human High-Metastatic Large Cell Lung Cancer Cell Line L9981
16
作者 Daxing ZHU Bin HU Xiaomin Q IU Ting WANG Yu FAN Li MA Jun CHEN Sen WEI Zhigang LI Hongyu LIU Haisu WAN Zhihao WU Qinghua ZHOU 《中国肺癌杂志》 CAS 2009年第6期515-517,共3页
Background and Objective Invasion and metastasis is not only the malignant phenotypes of lung cancer but also the main cause of death. To study and elucidate the molecular mechanism
关键词 NM23-H1 肺癌 治疗 疗效
下载PDF
马钱苷抑制NF-κB通路对A549肺癌细胞增殖、凋亡、侵袭的影响
17
作者 肖琳 宣立功 +3 位作者 甄伟 张静 冯妍 屈扬扬 《临床肺科杂志》 2024年第8期1234-1239,共6页
目的 探讨马钱苷对人非小细胞肺癌A549细胞增殖、凋亡和侵袭的影响及其作用机制。方法 不同浓度马钱苷处理A549细胞后,CCK-8实验检测细胞增殖抑制作用及半数抑制率(IC50);将A549细胞分为对照组、马钱苷低剂量组、马钱苷中剂量组、马钱... 目的 探讨马钱苷对人非小细胞肺癌A549细胞增殖、凋亡和侵袭的影响及其作用机制。方法 不同浓度马钱苷处理A549细胞后,CCK-8实验检测细胞增殖抑制作用及半数抑制率(IC50);将A549细胞分为对照组、马钱苷低剂量组、马钱苷中剂量组、马钱苷高剂量组和Diprovocim组,显微镜下观察A549细胞形态,细胞划痕实验检测迁移能力,Transwell实验测定细胞的侵袭能力,流式细胞术检测细胞凋亡,Western Blot技术验证环氧合酶(COX)-2、基质金属蛋白酶(MMP)-2、MMP-9、磷酸化(p)-p65、p65蛋白表达。结果 马钱苷抑制A549细胞的增殖(P<0.05);与对照组相比,马钱苷低、中、高剂量组可见悬浮细胞、大部分细胞脱落、细胞皱缩变圆且丝状伪足减少,细胞迁移和侵袭能力以及COX-2、MMP-2、MMP-9、p-p65/p65蛋白表达水平显著下降,凋亡率显著提高(P<0.05);与马钱苷高剂量组相比,Diprovocim组细胞生长状态良好,细胞迁移和侵袭能力以及COX-2、MMP-2、MMP-9、p-p65/p65蛋白表达水平显著提高,凋亡率显著降低(P<0.05)。结论 马钱苷通过抑制核因子-κB通路抑制A549细胞的增殖和侵袭能力,促进细胞凋亡。 展开更多
关键词 马钱苷 人非小细胞肺癌a549细胞 核因子-κB通路 增殖 凋亡
下载PDF
Inhibition Mechanism of Novel Pyrazolo[1,5-a]pyrazin-4(5H)-one Derivatives Against Proliferation of A549 and H322 Cancer Cells
18
作者 Jin-hui Shao Gui-hua Feng 《Chinese Medical Sciences Journal》 CAS CSCD 2015年第4期260-265,共6页
Objective To explore the inhibition mechanism and safety of pyrazolo[1,5-a]pyrazin-4(5H)-one derivatives against proliferation of human lung cancer A549 cells, H322 cells, and human umbilical vein endothelial cell(HUV... Objective To explore the inhibition mechanism and safety of pyrazolo[1,5-a]pyrazin-4(5H)-one derivatives against proliferation of human lung cancer A549 cells, H322 cells, and human umbilical vein endothelial cell(HUVEC). Methods Cells were treated with 40 μmol/L of the ppo3 a, ppo3 b, ppo3 i, and 0.1% DMSO(control) for 48 hours, respectively. Apoptosis was determined by Hoechst 33258 staining assay in H322 and A549 cells. Cell cycle distribution was determined by flow cytometry analysis in A549 cell. LC3-II, p53, and heat shock protein(HSP) 70 protein levels were detected by Western blotting in A549 cells treated with ppo3 b for 48 hours. The morphology and viability of HUVEC were observed by inverted microscope and sulforhodamine B(SRB) assay. Results Ppo3 a, ppo3 b, and ppo3 i significantly induced apoptosis in H322 and A549 cells. A strong G1-phase arrest was concomitant with the growth inhibitory effect on A549 cells. Ppo3 b effectively elevated the p53 protein level, but significantly reduced the HSP70 protein level. There were no significantly inhibitory effect on the morphology and viability of HUVEC when treated with ppo3 a, ppo3 b, and ppo3 i. Conclusions ppo3 a, ppo3 b, and ppo3 i could inhibit H322 proliferation through apoptosis and inhibit A549 through apoptosis and G1-phase arrest. The protein p53 and HSP70 might involve in the inhibition effects. These derivatives might be a clue to find effective and safe drug for lung cancers. 展开更多
关键词 PYRAZOLE apoptosis lung cancer cell P5 3 human UMBILICAL VEIN endothelial cell
下载PDF
Study of Pravastatin on Intervention of the Apoptosis in Human Lung Adenocarcinoma A549
19
作者 Chundi ZHANG 《International Journal of Technology Management》 2015年第6期104-106,共3页
Lung cancer is one of the serious threats to human health and life of malignant diseases, on a global scale; it has become one of the major lung cancer deaths. Due to the growth of the tumor and the main reason is tha... Lung cancer is one of the serious threats to human health and life of malignant diseases, on a global scale; it has become one of the major lung cancer deaths. Due to the growth of the tumor and the main reason is that apoptosis is inhibited, therefore, it can induce apoptosis in lung cancer cells that is an important measure for the treatment of lung cancer, which is one of the effective means to reduce lung cancer mortality. In this paper, A549 human lung adenocarcinoma cell line, for example, has the use of chemical genetics of these emerging technological platforms, research pravastatin on apoptosis in human lung adenocarcinoma A549 intervention, while providing a theoretical basis for the development of new lung cancer therapy. 展开更多
关键词 PRAVASTATIN human lung Adenocarcinoma a549 cells APOPTOSIS RESEARCH
下载PDF
益气养阴散结方对A549裸鼠肿瘤脂滴相关蛋白与脂代谢相关蛋白的影响
20
作者 杨雪飞 张志娣 +4 位作者 黄挺 傅晓青 叶知锋 郭俊华 刘冰 《浙江中西医结合杂志》 2023年第3期205-210,共6页
目的探讨益气养阴散结方对A549裸鼠肿瘤脂滴相关蛋白、脂代谢相关蛋白的影响。方法取4~6周龄BALB/c裸鼠30只,皮下接种A549细胞株以复制肺腺癌小鼠模型,按照随机数字表法分为五组,模型组、顺铂组和益气养阴散结方低、中、高剂量组,每组6... 目的探讨益气养阴散结方对A549裸鼠肿瘤脂滴相关蛋白、脂代谢相关蛋白的影响。方法取4~6周龄BALB/c裸鼠30只,皮下接种A549细胞株以复制肺腺癌小鼠模型,按照随机数字表法分为五组,模型组、顺铂组和益气养阴散结方低、中、高剂量组,每组6只。接种次日起给药,模型组给予生理盐水0.3 mL/d;顺铂组给予顺铂4 mg/kg,每周2次;益气养阴散结方低、中、高剂量组给予5、10、20 g/(kg·d)益气养阴散结方,连续给药8周。采用免疫印迹、免疫组化检测脂周素-1(perilipin-1)、脂滴蛋白5(LSDP5)、47kDa尾连蛋白(TIP47)、脂肪分化相关蛋白(ADRP)、脂肪细胞型脂肪酸结合蛋白(A-FABP)、Delta样因子-1(DLK-1)、小窝蛋白-1(caveolin-1)等脂滴相关蛋白、脂代谢相关蛋白在肿瘤中的表达。结果30只裸鼠成瘤,成瘤率100%。在实验期内,模型组和益气养阴散结方中剂量组各死亡裸鼠1只。免疫印迹结果表明,与模型组比较,益气养阴散结方低、高剂量组显著下调脂滴相关蛋白、脂代谢相关蛋白的表达[perilipin-1:(0.76±0.23)、(0.58±0.18)比(0.93±0.22);LSDP5:(0.79±0.23)、(0.38±0.11)比(1.06±0.30);TIP47:(0.49±0.19)、(0.24±0.06)比(0.71±0.25);ADRP:(0.48±0.15)、(0.27±0.08)比(0.61±0.17);A-FABP:(0.52±0.14)、(0.31±0.09)比(0.59±0.19);DLK1:(0.75±0.23)、(0.64±0.08)比(1.07±0.21);caveolin-1:(0.60±0.25)、(0.41±0.09)比(1.09±0.31),P<0.05或P<0.01]。免疫组化结果表明,与模型组比较,益气养阴散结方中、高剂量组显著下调脂滴相关蛋白、脂代谢相关蛋白的表达[perilipin-1:(4.17±0.32)、(3.90±0.57)比(5.70±0.97);TIP47:(5.13±0.50)、(3.73±0.31)比(5.67±0.70);ADRP:(4.67±1.01)、(4.17±0.61)比(6.13±0.81);AFABP:(4.02±0.40)、(3.40±0.23)比(5.67±0.75);caveolin-1:(5.03±0.50)、(4.23±0.35)比(6.33±0.93),P<0.05或P<0.01],高剂量组下调DLK1表达[(5.10±0.40)比(7.93±0.91),P<0.01]。结论高剂量益气养阴散结方可显著降低perilipin-1、LSDP5、TIP47、ADRP、A-FABP、DLK1、caveolin-1等脂滴相关蛋白、脂代谢相关蛋白在A549裸鼠肿瘤中的表达。 展开更多
关键词 裸鼠 非小细胞肺癌 人肺腺癌细胞株a549 益气养阴散结方 脂滴相关蛋白 脂代谢相关蛋白
下载PDF
上一页 1 2 33 下一页 到第
使用帮助 返回顶部